Edit

Emergent BioSolutions

http://www.emergentbiosolutions.com/

Last activity: 29.06.2026

Active

Categories: AdTechDevelopmentHealthTechLifeManufacturingProductPublicServiceSocialSpecialty

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Followers

2.57K

Followers

28.33K

Website visits

45.2K /mo.

Mentions

Location: United States, Maryland, Gaithersburg

Employees: 1001-5000

Total raised: $52.7M

Founded date: 1998

Investors 2

Date	Name	Website
17.07.2021	ARCH Ventu...	archventur...
-	Advent Lif...	adventls.c...

Funding Rounds 1

Date	Series	Amount	Investors
29.06.2026	-	$52.7M	-

Mentions in press and media 25

Date	Title	Description
29.06.2026	Emergent BioSolutions Secures $52.7 Million U.S. Government Contract Modification For ACAM2000	Emergent BioSolutions announced that it has been awarded a contract modification valued at approximately $52.7 million from the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. The ...
11.05.2026	Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile	Several pharmaceutical stocks have surged in wake of a hantavirus outbreak as investors gauge whether they could benefit from developing vaccines. Moderna, Inovio, and Novavax surged in early trading Monday, but couldn’t sustain some of the...
06.02.2026	PDA Introduces the 2026 Board of Directors and Officers	PDA's diverse Board of Directors brings a diverse set of interests, expertise, and experiences. BETHESDA, Md., Feb. 6, 2026 /PRNewswire-PRWeb/ -- PDA is excited to introduce the all-volunteer 2026 Board of Directors and Officers following f...
11.11.2025	PDA Releases Three New Foundational Documents to Advance Aseptic Processing and Sterilizing Filtration Practices	These documents reflect PDA's ongoing dedication to providing the pharmaceutical industry with high-quality, practical resources that promote excellence in sterile product manufacturing. BETHESDA, Md., Nov. 11, 2025 /PRNewswire-PRWeb/ -- Th...
13.10.2025	China’s MGI Gains After Licensing Gene Sequencing Tech to Swiss Rockets for USD120 Million	(Yicai) Oct. 13 -- MGI Tech’s stock price rose after the Chinese supplier of gene-sequencing gear agreed to license the regional marketing rights for its CoolMPS technology to Swiss Rockets for USD120 million. After jumping by as much as 9 ...
05.08.2025	Biggest Funding Rounds in Serbia (H1 2025)	Serbia ~ Company: Below, you can find the biggest H1 2025 funding rounds in Serbia, along with key details about the startups. Check the rest of the Central and Eastern Europe H1 2025 mappings here. This article is part of the CEE funding m...
20.03.2025	Syngene completes US biologics site acquisition, shares trade flat	Syngene International had informed the exchanges late last night that Syngene USA has completed the acquisition of its first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSoluti...
14.03.2025	Swiss Rockets obtains strategic investment	Rocketvax Ltd one of Switzerland’s next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies. One of Rocketvax’s leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has demonstrat...
10.03.2025	Syngene acquires first US facility from Emergent Manufacturing	Syngene International, the contract research wing of Biocon Group, has acquired its first manufacturing facility in the US from Emergent Manufacturing Operations Baltimore. The pharma player has invested around $50 million, including the co...
27.01.2025	The 2025 PDA Board of Directors: A Diverse Range of Interests and Expertise	The 2025 PDA Board of Directors The officers and directors represent pharmaceutical/biopharmaceutical businesses of all sizes and areas of competency across the United States, Europe and Asia. BETHESDA, Md., Jan. 27, 2025 /PRNewswire-PRWeb/...
06.08.2024	Back-to-school shopping? Here's one item to add to your cart	Sorry, but your browser does not support the video tag. (BPT) - Do you have a teenager or young adult heading back to school this year? Are you looking for peace of mind that they will stay safe? While picking up school supplies, clothing, ...
11.03.2024	Global Anthrax Vaccine Market Worth Over $22 Billion by 2034, Driven by Advanced Vaccine Developments and Rising Demand for Bioterrorism Defense	-
06.03.2024	Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results	-
16.05.2022	Emergent inks $225M cash smallpox deal as Chimerix implodes on reorg, FDA trouble	Emergent BioSolutions has made a name for itself ever since the late 1990s by making drugs that are needed by the US government. Monday, it took that a step further, as it entered a deal with Chimerix to acquire the exclusive ...
10.05.2022	Emergent tossed nearly 400M Covid-19 vaccine doses in Baltimore debacle, House report says	The exact number of doses lost in the Emergent BioSolutions mishap at its Baltimore plant has never been exactly determined. But a recent report from the US House select subcommittee on the coronavirus crisis says that...
05.01.2022	Teva and Novartis’ Sandoz launch Narcan generics on same day, brand marketer Emergent remains in play	Teva and Novartis’ Sandoz recently launched generic versions of Narcan on the same day, but it likely wasn’t a coincidence. Both first-to-market generics for Narcan, an opioid overdose rescue nasal spray, are FDA approve...
12.11.2021	Emergent BioSolutions Inc. announces an Equity Buyback for $250 million worth of its shares.	Emergent BioSolutions Inc. (NYSE:EBS) announces a share repurchase program. Under the program, the company will repurchase up to $250 million worth of its common stock. Any repurchased shares will be held in treasury shares and will be avai...
04.04.2021	J&J Takes Over at Emergent Vaccine Plant With Aid From Biden J&J Takes Over at Emergent Vaccine Plant With Aid From Biden	(Bloomberg) -- Johnson & Johnson, with help from the Biden administration, is taking over a Baltimore vaccine production facility that was the site of a major manufacturing error last month -- and moving production of material for a sec...
03.04.2020	Emergent BioSolutions gets $14.5M in federal funding to expedite COVID-19 plasma therapy development	Last week, we spoke to the head of Emergent BioSolutions’ Therapeutics Business Unit Dr. Laura Saward about her company’s work developing plasma-based potential treatments for COVID-19. Now, the company announced that it has received $14.5 ...
25.03.2020	How one company is fast-tracking development of potential plasma-based treatments for the coronavirus	Medical biotech company Emergent BioSolutions is one of the many health industry players turning its efforts towards addressing the current global coronavirus pandemic. Their work includes a two-pronged effort to pursue plasma-based treatme...
17.09.2018	Here’s a look at Maryland’s publicly-traded biotech companies	When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ...
10.08.2018	Emergent BioSolutions to Acquire Vaccines Company PaxVax, for $270M	Emergent BioSolutions Inc. (NYSE: EBS) is to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for $270m. PaxVax is majority owned by an affiliate of Cerberus Capital Man...
17.03.2015	Emergent Biosolutions’ latest product could make Ebola vaccines stronger	Even as the Ebola crisis fades in and out of the headlines, the quest to develop a vaccine against the virus continues. On Monday, officials announced another role that Baltimore’s burgeoning biotech community is playing in the development ...
09.02.2015	Citelighter teams up with Encyclopedia Britannica [Startup Roundup]	WHO’S GETTING FUNDED Biotech continues to attract a lot of money to Baltimore. Over the last week, a pair of local companies got sizable grants to boost their Baltimore operations. Emergent Biosolutions received a $2 million grant from the ...
-	Addressing awareness and accessibility with over-the-counter NARCAN® Nasal Spray	Far too many Americans have been personally impacted by the opioid crisis. Recent data shows over 105,000 drug overdose deaths, with most of these fatalities opioid-related, occurring in the 12-month period ending in December 2022. The rece...

Emergent BioSolutions

Investors 2

Funding Rounds 1

Mentions in press and media 25

Reviews 0